FY2024 EPS Estimates for AxoGen Lifted by Leerink Partnrs

AxoGen, Inc. (NASDAQ:AXGN) – Equities researchers at Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for shares of AxoGen in a research report issued to clients and investors on Monday, November 25th. Leerink Partnrs analyst M. Kratky now forecasts that the medical equipment provider will post earnings per share of ($0.31) for the year, up from their prior forecast of ($0.32). The consensus estimate for AxoGen’s current full-year earnings is ($0.30) per share. Leerink Partnrs also issued estimates for AxoGen’s Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.06) EPS, FY2026 earnings at $0.17 EPS, FY2027 earnings at $0.26 EPS and FY2028 earnings at $0.34 EPS.

A number of other analysts have also recently issued reports on the stock. JMP Securities lifted their target price on shares of AxoGen from $17.00 to $20.00 and gave the company a “market outperform” rating in a research note on Friday, August 9th. StockNews.com raised shares of AxoGen from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $15.00.

AxoGen Trading Up 3.4 %

Shares of NASDAQ AXGN opened at $14.07 on Wednesday. The business has a 50 day simple moving average of $13.70 and a 200 day simple moving average of $10.76. AxoGen has a 52 week low of $5.55 and a 52 week high of $15.90. The stock has a market cap of $619.22 million, a price-to-earnings ratio of -43.97 and a beta of 1.13. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74.

Institutional Investors Weigh In On AxoGen

A number of large investors have recently added to or reduced their stakes in the stock. First Light Asset Management LLC grew its position in shares of AxoGen by 336.6% in the second quarter. First Light Asset Management LLC now owns 3,344,033 shares of the medical equipment provider’s stock valued at $24,211,000 after purchasing an additional 2,578,147 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in AxoGen by 2,014.6% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,310,811 shares of the medical equipment provider’s stock valued at $9,490,000 after buying an additional 1,248,823 shares during the last quarter. Geode Capital Management LLC grew its holdings in AxoGen by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,010,508 shares of the medical equipment provider’s stock valued at $14,170,000 after buying an additional 31,612 shares during the last quarter. State Street Corp boosted its position in shares of AxoGen by 11.9% in the third quarter. State Street Corp now owns 896,674 shares of the medical equipment provider’s stock valued at $12,571,000 after acquiring an additional 95,051 shares during the period. Finally, Silvercrest Asset Management Group LLC boosted its position in shares of AxoGen by 4.5% in the first quarter. Silvercrest Asset Management Group LLC now owns 790,647 shares of the medical equipment provider’s stock valued at $6,381,000 after acquiring an additional 34,399 shares during the period. Institutional investors own 80.29% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.